Reccurence of endometrioid ovarian cysts and possible ways to its reduce
Aim. Comparative evaluation of the effectiveness of various types of hormone therapy for the prevention of relapses of endometrioid cysts (EC), based on clinical observation and data analysis. Materials and methods. Retrospective analysis of 122 patients (the average age 31.76.12 years) with lapar...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Berlin A.V.
2020-07-01
|
| Series: | Гинекология |
| Subjects: | |
| Online Access: | https://gynecology.orscience.ru/2079-5831/article/viewFile/34977/pdf |
| _version_ | 1798028717873692672 |
|---|---|
| author | Dmitrii V. Gusev Viktoriia Yu. Prilutskaya Galina E. Chernukha |
| author_facet | Dmitrii V. Gusev Viktoriia Yu. Prilutskaya Galina E. Chernukha |
| author_sort | Dmitrii V. Gusev |
| collection | DOAJ |
| description | Aim. Comparative evaluation of the effectiveness of various types of hormone therapy for the prevention of relapses of endometrioid cysts (EC), based on clinical observation and data analysis.
Materials and methods. Retrospective analysis of 122 patients (the average age 31.76.12 years) with laparoscopically confirmed endometriosis. Patients were divided into groups, according to the treatment options aGnRH (n=11), COCs (n=13), dienogest (Visanne) (n=56). A comparison group included 42 patients who did not receive hormone therapy. There were evaluated the number of reccurence in the group without therapy and in groups with different options for hormonal therapy.
Results. Among patients treated with hormone therapy, the recurrence rate of EC was 3.75%, among those who have not received therapy 38.1%. Of these, 31.1% of patients had recurrence rate of EC during the first year, 37.8% during 3 years, and 31.1% after 3 years. After suppressive therapy was discontinued, the relapse rate in the aGnRH group was 63.6%, COC 50%, dienogest 24%.
Conclusions. In addition to evaluating the ovarian reserve before and after surgical treatment, management tactics for patients with EC should include the long-term administration of dienogest as an anti-relapse therapy. |
| first_indexed | 2024-04-11T19:12:25Z |
| format | Article |
| id | doaj.art-f1a05bdaa12644dd86728e0ab0a18e0a |
| institution | Directory Open Access Journal |
| issn | 2079-5696 2079-5831 |
| language | Russian |
| last_indexed | 2024-04-11T19:12:25Z |
| publishDate | 2020-07-01 |
| publisher | IP Berlin A.V. |
| record_format | Article |
| series | Гинекология |
| spelling | doaj.art-f1a05bdaa12644dd86728e0ab0a18e0a2022-12-22T04:07:34ZrusIP Berlin A.V.Гинекология2079-56962079-58312020-07-01223343810.26442/20795696.2020.3.20014431388Reccurence of endometrioid ovarian cysts and possible ways to its reduceDmitrii V. Gusev0Viktoriia Yu. Prilutskaya1Galina E. Chernukha2Kulakov National Medical Research Center for Obstetrics, Gynecology and PerinatologySechenov First Moscow State Medical University (Sechenov University)Kulakov National Medical Research Center for Obstetrics, Gynecology and PerinatologyAim. Comparative evaluation of the effectiveness of various types of hormone therapy for the prevention of relapses of endometrioid cysts (EC), based on clinical observation and data analysis. Materials and methods. Retrospective analysis of 122 patients (the average age 31.76.12 years) with laparoscopically confirmed endometriosis. Patients were divided into groups, according to the treatment options aGnRH (n=11), COCs (n=13), dienogest (Visanne) (n=56). A comparison group included 42 patients who did not receive hormone therapy. There were evaluated the number of reccurence in the group without therapy and in groups with different options for hormonal therapy. Results. Among patients treated with hormone therapy, the recurrence rate of EC was 3.75%, among those who have not received therapy 38.1%. Of these, 31.1% of patients had recurrence rate of EC during the first year, 37.8% during 3 years, and 31.1% after 3 years. After suppressive therapy was discontinued, the relapse rate in the aGnRH group was 63.6%, COC 50%, dienogest 24%. Conclusions. In addition to evaluating the ovarian reserve before and after surgical treatment, management tactics for patients with EC should include the long-term administration of dienogest as an anti-relapse therapy.https://gynecology.orscience.ru/2079-5831/article/viewFile/34977/pdfendometriosisendometrioid cystdienogestgnrh agonists |
| spellingShingle | Dmitrii V. Gusev Viktoriia Yu. Prilutskaya Galina E. Chernukha Reccurence of endometrioid ovarian cysts and possible ways to its reduce Гинекология endometriosis endometrioid cyst dienogest gnrh agonists |
| title | Reccurence of endometrioid ovarian cysts and possible ways to its reduce |
| title_full | Reccurence of endometrioid ovarian cysts and possible ways to its reduce |
| title_fullStr | Reccurence of endometrioid ovarian cysts and possible ways to its reduce |
| title_full_unstemmed | Reccurence of endometrioid ovarian cysts and possible ways to its reduce |
| title_short | Reccurence of endometrioid ovarian cysts and possible ways to its reduce |
| title_sort | reccurence of endometrioid ovarian cysts and possible ways to its reduce |
| topic | endometriosis endometrioid cyst dienogest gnrh agonists |
| url | https://gynecology.orscience.ru/2079-5831/article/viewFile/34977/pdf |
| work_keys_str_mv | AT dmitriivgusev reccurenceofendometrioidovariancystsandpossiblewaystoitsreduce AT viktoriiayuprilutskaya reccurenceofendometrioidovariancystsandpossiblewaystoitsreduce AT galinaechernukha reccurenceofendometrioidovariancystsandpossiblewaystoitsreduce |